Active-Controlled, Double-Blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density

Trial Profile

Active-Controlled, Double-Blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2013

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 01 Feb 2009 Results have been published in Clinical Therapeutics.
    • 13 Feb 2008 New trial record.
    • 06 Jun 2006 Results have been presented at the International Osteoporosis Foundation World Congress on Osteoporosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top